35674-28-3

Usage

Synthesis Reference(s)

Journal of Medicinal Chemistry, 30, p. 303, 1987 DOI: 10.1021/jm00385a012

InChI:InChI=1/C7H4INO4/c8-4-1-2-6(9(12)13)5(3-4)7(10)11/h1-3H,(H,10,11)

Upstream product

• 99-05-8 meta-aminobenzoic acid 
• 52415-00-6 4-iodo-2-methyl-1-nitro-benzene 
• 618-51-9 3-Iodobenzoic acid 
• 7697-37-2 nitric acid 
• 13280-60-9 5-amino-2-nitrobenzoic acid 

Downstream Products

• 105727-90-0 N-cyclohexyl-N-methyl-5-(1,2,3,5-tetrahydro-2-oxoimidazo<2,1-b>quinazolin-7-yl)pentanamide 
• 105728-32-3 methyl 5-(3-formyl-4-nitrophenyl)-4-pentynoate 
• 105728-31-2 5-iodo-2-nitrobenzaldehyde 
• 5326-47-6 2-amino-5-iodobenzoic acid 
• 914778-18-0 7-diethylamino-2-oxo-2H-chromene-3-carboxylic acid 5-iodo-2-nitrobenzyl ester 
• 914777-95-0 5-(4-methoxy-phenylethynyl)-2-nitrobenzyl alcohol 
• 914777-96-1 5-(4-methoxy-phenylethylene)-2-nitrobenzyl alcohol 
• 53279-83-7 (2-amino-5-iodophenyl)methanol 
• 150022-33-6 (5-iodo-2-nitrophenyl)methanol 

Relevant academic research and scientific papers

Synthesis of novel quinazolinone derivatives with methyl (E)-2-(3-methoxy)acrylate moiety

A new series of quinazolinone derivatives with methyl (E)-2-(3-methoxy) acrylate moiety have been designed and synthesized. All target compounds had been identified by 1H NMR spectrum, IR spectrum and HR-MS (high resolution mass spectrum). Three target compounds (10a, 10e, 10h) were chosen to preliminarily test the antibacterial activities, the results showed that all three target compounds exhibited antibacterial activities against three bacterial strains (Proteobacteria, Salmonella, Colibacillus).

O-nitrobenzyl photolabile protecting groups with red-shifted absorption: Syntheses and uncaging cross-sections for one- And two-photon excitation

We evaluated the o-nitrobenzyl platform for designing photolabile protecting groups with red-shifted absorption that could be photolyzed upon one- and two-photon excitation. Several synthetic pathways to build different conjugated o-nitrobenzyl backbones,

Ester derivatives and medicinal use thereof

The present invention relates to an ester represented by the formula [1]: or its pharmaceutically acceptable salt, or use of the same. The compound represented by the formula [1] or its pharmaceutically acceptable salt is useful as an agent for the treatment or prophylaxis of hyperlipidemia or the like, since it disappears very rapidly in the living body and has an excellent MTP inhibitory activity.

Inhibitors of Cyclic AMP Phosphodiesterase. 2. Structural Variations of N-Cyclohexyl-N-methyl-4-quinazolin-7-yl)oxy>butyramide (RS-82856)

A series of analogues of the cyclic AMP phosphodiesterase (PDE) inhibitor N-cyclohexyl-N-methyl-4-quinazolin-7-yl)oxy>butyramide (RS-82856, 1) was prepared by systematic variation of the side-chain substituent, length, position, connecting atom, and the parent heterocycle itself.The compounds were evaluated as inhibitors of cyclic AMP phosphodiesterase from both human platelets and rat or dog heart tissue and as inhibitors of ADP-induced platelet aggregation.Structure-activity correlations for the analogue series revealed significant limitations on the steric bulk of substituents on the 1,2,3,5-tetrahydroimidazoquinaazolin-2-one heterocycle and the position and length of the side-chain.As inhibitors of cyclic AMP phosphodiesterase (PDE), potency steadily increased with increasingly lipophilic side chains.In platelet aggregation inhibition studies, however, a maximum in activity was reached with 1, while more lipophilic compounds were significantly less active.Major changes in the heterocycle itself, represented by isomeric and other carbonyl variations, also decreased activity.The molecular features defined by this series of analogues of 1 correlate to a high degree with current understanding of thr chemical and topographical requirements of the active site of the FIII (type IV) form of cyclic AMP PDE.Selective inhibition of this enzyme has been proposed as the principal component of the positive inotropic action of a number of cardiotonic agents.